Literature DB >> 30564847

Ultrasound-guided low thoracic paravertebral block versus peritubal infiltration for percutaneous nephrolithotomy: a prospective randomized study.

Ahmet Murat Yayik1,2, Ali Ahiskalioglu3, Saban Oguz Demirdogen4, Elif Oral Ahiskalioglu5, Haci Ahmet Alici3, Husnu Kursad3.   

Abstract

The aim of this study was to investigate the efficacy of peritubular infiltration and ultrasound-guided low thoracal paravertebral block in patients undergoing percutaneous nephrolithotomy (PCNL). Sixty patients, American Society of Anesthesiologists I-II, between the ages of 18 and 65 years undergoing PCNL were randomized into three groups. Group peritubal infiltration (Pi, n = 20) received infiltration along the nephrostomy tube 20 ml 0.25% bupivacaine, in 6 and 12 o'clock position. Group paravertebral block (Pv, n = 20) received single-shot paravertebral block with 20 ml 0.25% bupivacaine at the level of T8-T9. Group control (C, n = 20): no intervention is performed. Postoperative opioid consumption and pain scores, opioid-related side effects, and additional analgesic requirement were recorded. The fentanyl consumption in Group Pv was significantly lower in comparison to Group C in all time intervals (p < 0.05). In the comparison of Group Pv and Group Pi, fentanyl consumptions in the postoperative 0-4th hours (100.00 ± 50.65 and 145.00 ± 61.55, respectively), 4-8th hours (50.00 ± 64.88 and 121.25 ± 56.93 respectively), and in the total of 24 h (197.50 ± 133.74 and 368.75 ± 116.66 respectively) were significantly lower in Group Pv (p < 0.05). The dynamic VAS scores analyzed at the 1st and 2nd hours were significantly lower in Group Pv than Group Pi (p < 0.05). Eight patients in Group C, two patients in Group Pi and 1 patient in Group Pv required additional analgesics and the difference was significant (p < 0.05). Paravertebral block achieved more effective analgesia by reducing postoperative opioid consumption and VAS scores comparison to the control and peritubal infiltration groups in patients undergoing percutaneous nephrolithotomy.

Entities:  

Keywords:  Paravertebral block; Percutaneus nephrolithotomy; Peritubal infiltration; Ultrasound

Mesh:

Substances:

Year:  2018        PMID: 30564847     DOI: 10.1007/s00240-018-01106-w

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  6 in total

1.  Risk factors for moderate-to-severe postoperative pain after percutaneous nephrolithotomy: a retrospective cohort study.

Authors:  Haotian Wu; Tianfu Ding; Siyi Yan; Zhongyue Huang; Huan Zhang
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

2.  The analgesic efficacy of paravertebral block for percutaneous nephrolithotomy: A meta-analysis of randomized controlled studies.

Authors:  Xiaoyu Tan; Donglin Fu; Wubing Feng; Xiangqi Zheng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Comparison of peritubal infiltration and single level T10 paravertebral block in percutaneous nephrolithotomy (PCNL).

Authors:  K Shankar; Srinivasan Rangalakshmi; D Priyanka; P Kailash; Vijaykumar Kadlimatti Deepak
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2022-01-06

Review 4.  The efficacy and safety of paravertebral block for postoperative analgesia in renal surgery: A systematic review and meta-analysis of randomized controlled trials.

Authors:  You Zhao; Yanan Kan; Xin Huang; Ming Wu; Weiping Luo; Jun Nie
Journal:  Front Surg       Date:  2022-07-18

5.  Retrospective study of quadratus lumborum block for postoperative analgesia in patients undergoing percutaneous nephrolithotomy.

Authors:  Luning Chen; Jingjing Ji; Yali Tian; Qing Sun; Xuefeng Qiu; Xiaogong Li; Bingbing Li
Journal:  BMC Anesthesiol       Date:  2020-08-31       Impact factor: 2.217

6.  Analgesic efficacy of ultrasound guided paravertebral block in percutaneous nephrolithotomy patients: a randomized controlled clinical study.

Authors:  Ferda Yaman; Devrim Tuglu
Journal:  BMC Anesthesiol       Date:  2020-09-29       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.